Li W - Search Results

1

Efficacy and safety of anlotinib combined with vinorelbine as second‑line treatment for elderly patients with advanced squamous cell lung carcinoma: A retrospective cohort.

Li Y, Li W, Liu Y, Peng Y, Tang J, Li X. Li Y, et al. Among authors: li w, li x. Mol Clin Oncol. 2024 Dec 19;22(2):21. doi: 10.3892/mco.2024.2816. eCollection 2025 Feb. Mol Clin Oncol. 2024. PMID: 39776939 Free PMC article.

2

Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis.

Lin L, Liu Y, Chen C, Wei A, Li W. Lin L, et al. Among authors: li w. Front Pharmacol. 2023 May 22;14:1190001. doi: 10.3389/fphar.2023.1190001. eCollection 2023. Front Pharmacol. 2023. PMID: 37284302 Free PMC article.

3

A meta-analysis of the efficacy of programmed cell death 1/its ligand inhibitors plus cytotoxic T-lymphocyte-associated antigen 4 inhibitors in non-small cell lung cancer.

Lin L, Xiao L, Li L, Chen C, Zhang H, Yu C, Zhang L, Wei A, Li W. Lin L, et al. Among authors: li w, li l. Front Pharmacol. 2024 Feb 5;15:1267763. doi: 10.3389/fphar.2024.1267763. eCollection 2024. Front Pharmacol. 2024. PMID: 38379896 Free PMC article.

4

Peripherally inserted central catheters versus implantable port catheters for cancer patients: a meta-analysis.

Lin L, Li W, Chen C, Wei A, Liu Y. Lin L, et al. Among authors: li w. Front Oncol. 2023 Jul 14;13:1228092. doi: 10.3389/fonc.2023.1228092. eCollection 2023. Front Oncol. 2023. PMID: 37519803 Free PMC article.

5

Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China.

Li W, Wan L. Li W, et al. BMJ Open. 2023 Sep 26;13(9):e074245. doi: 10.1136/bmjopen-2023-074245. BMJ Open. 2023. PMID: 37751954 Free PMC article.

6

Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China.

Li W, Wan L. Li W, et al. Expert Rev Pharmacoecon Outcomes Res. 2024 Jun;24(5):671-678. doi: 10.1080/14737167.2024.2341859. Epub 2024 Apr 11. Expert Rev Pharmacoecon Outcomes Res. 2024. PMID: 38594905 Clinical Trial.

7

Cost-effectiveness of tislelizumab plus chemotherapy vs chemotherapy as first-line treatment of PD-L1 positive advanced gastric or gastroesophageal junction adenocarcinoma from a Chinese perspective.

Li W, Wan L, Zhang J. Li W, et al. Expert Rev Gastroenterol Hepatol. 2024 Jun;18(6):293-301. doi: 10.1080/17474124.2024.2373730. Epub 2024 Jun 28. Expert Rev Gastroenterol Hepatol. 2024. PMID: 38923910

8

Interleukin-23 receptor defines T helper 1-like regulatory T cells in oral squamous cell carcinoma.

Li W, An N, Wang M, Liu X, Mei Z. Li W, et al. Immun Inflamm Dis. 2022 Dec;10(12):e746. doi: 10.1002/iid3.746. Immun Inflamm Dis. 2022. PMID: 36444617 Free PMC article.

9

Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China.

Li W, Wan L. Li W, et al. Front Public Health. 2022 Nov 3;10:1015702. doi: 10.3389/fpubh.2022.1015702. eCollection 2022. Front Public Health. 2022. PMID: 36408023 Free PMC article. Clinical Trial.

10

Development and validation of a novel disulfidptosis-related lncRNAs signature in patients with HPV-negative oral squamous cell carcinoma.

Yang F, Niu X, Zhou M, Li W. Yang F, et al. Among authors: li w. Sci Rep. 2024 Jun 23;14(1):14436. doi: 10.1038/s41598-024-65194-y. Sci Rep. 2024. PMID: 38910181 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

82,580 results

Search Page

Filters